PARP Inhibitors Market
完整報告名稱與涵蓋範圍
PARP Inhibitors Market Size, Share & Trends Analysis Report By Product (Niraparib (Zejula), Olaparib (Lynparza), Rucaparib (Rubraca), Talazoparib (Talzenna), Veliparib, Other Pipeline Drugs), By Indication, By Region, And By Segment Forecasts, 2025-2034
報告摘要
The PARP Inhibitors Market on a global scale was estimated at USD 3.8 Billion in 2024 and is poised to attain USD 15.5 Billion by 2034, with a projected CAGR of 15.2% between 2025 and 2034.
The PARP Inhibitors sector involves a constituent that blocks the parp enzyme in the cell. This domain has witnessed meaningful transformation owing to technological breakthroughs and shifting healthcare dynamics.
Several factors contribute to this trajectory, including heightened interest in next-generation products, expanding applications across diverse end-use sectors, and supportive government initiatives.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region poised to deliver the strongest growth trajectory through the forecast period, underpinned by demographic shifts and policy support.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global PARP Inhibitors Market Snapshot
Chapter 4. Global PARP Inhibitors Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Penetration & Growth Prospect Mapping
4.6. Clinical Trial/Pipeline Analysis
4.7. Industry Analysis – Porter's Five Forces Analysis
4.8. Competitive Landscape & Market Share Analysis
4.9. Technology Advancement in PARP Inhibitors
4.10. Key Trends in the Market
Chapter 5. Market Segmentation 1: Product Estimates & Trend Analysis
5.1. Product Type & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Product:
5.2.1. Niraparib (Zejula)
5.2.2. Olaparib (Lynparza)
5.2.3. Rucaparib (Rubraca)
5.2.4. Talazoparib (Talzenna)
5.2.5. Veliparib
5.2.6. Other Pipeline Drugs
Chapter 6. PARP Inhibitors Market Segmentation 2: Indication Estimates & Trend Analysis
6.1. Indication Analysis & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Indication:
6.2.1. Ovarian Cancer
6.2.2. Breast cancer
6.2.3. Prostate and Pancreatic Cancer
Chapter 7. PARP Inhibitors Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America PARP Inhibitors Market revenue (US$ Million) estimates and forecasts by product, 2021-2034
7.1.2. North America PARP Inhibitors Market revenue (US$ Million) estimates and forecasts by indication, 2021-2034
7.1.3. North America PARP Inhibitors Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
7.2. Europe
7.2.1. Europe PARP Inhibitors Market revenue (US$ Million) by product, 2021-2034
7.2.2. Europe PARP Inhibitors Market revenue (US$ Million) by indication, 2021-2034
7.2.3. Europe PARP Inhibitors Market revenue (US$ Million) by country, 2021-2034
7.3. Asia Pacific
7.3.1. Asia Pacific PARP Inhibitors Market revenue (US$ Million) by product, 2021-2034
7.3.2. Asia Pacific PARP Inhibitors Market revenue (US$ Million) by indication, 2021-2034
7.3.3. Asia Pacific PARP Inhibitors Market revenue (US$ Million) by country, 2021-2034
7.4. Latin America
7.4.1. Latin America PARP Inhibitors Market revenue (US$ Million) by product, (US$ Million)
7.4.2. Latin America PARP Inhibitors Market revenue (US$ Million) by indication, (US$ Million)
7.4.3. Latin America PARP Inhibitors Market revenue (US$ Million) by country, (US$ Million) 2021-2034
7.5. MEA
7.5.1. MEA revenue PARP Inhibitors Market revenue (US$ Million) by product, (US$ Million) 2021-2034
7.5.2. MEA revenue PARP Inhibitors Market revenue (US$ Million) by indication, (US$ Million) 2021-2034
7.5.3. MEA revenue PARP Inhibitors Market revenue (US$ Million) by country, (US$ Million) 2021-2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1 Johnson & Johnson Services, Inc.
8.2.2 Merck KGaA
8.2.3 GSK plc.
8.2.4 Pfizer Inc.
8.2.5 AbbVie Inc.
8.2.6 Teva Pharmaceutical Industries Ltd.
8.2.7 Artios Pharma
8.2.8 Genentech, Inc.
8.2.9 Karyopharm Therapeutics Inc.
8.2.10 Repare Therapeutics Inc
8.2.11 ONO PHARMACEUTICAL CO., LTD
8.2.12 Jiangsu Hengrui Pharma Co., Ltd.
8.2.13 Bristol-Myers Squibb Co
8.2.14 AstraZeneca plc
8.2.15 Checkpoint Therapeutics, Inc.
8.2.16 Eisai Co., Ltd.
8.2.17 IMPACT Therapeutics
8.2.18 JEIL PHARMA CO.,LTD.
8.2.19 Kyowa Kirin Co., Ltd
8.2.20 SyntheX
8.2.28. Other Prominent Players
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們